Patents Represented by Attorney Aaron L. Schwartz
-
Patent number: 7569682Abstract: The present invention relates to nucleic acid sequences encoding a 30 kD Brachyspira hyodysenteriae lipoprotein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such lipoproteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relates to a 30 kD Brachyspira hyodysenteriae lipoprotein and immunogenic parts thereof encoded by such sequences. Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, lipoproteins or immunogenic parts thereof and antibodies against such lipoproteins or immunogenic parts thereof. Also, the invention relates to the use of said lipoproteins in vaccines and for the manufacture of vaccines.Type: GrantFiled: August 3, 2007Date of Patent: August 4, 2009Assignee: Intervet International B.V.Inventors: Ben Adler, Paul Antony Cullen, Scott Adam James Coutts, Dieter Mark Bulach, Ruud Philip Antoon Maria Segers
-
Patent number: 7563881Abstract: The present invention relates to a new polynucleotide that encodes a polypeptide involved in cellular entrance of PRRSV, to a recombinant vector comprising said polynucleotide, to a cell capable of expressing said polypeptide, a method of producing said polypeptide as well as to cell culture and to a novel method of producing the PRRSV virus. The present invention further relates to a method of identifying compounds that affect the PRRSV receptor function of the polypeptide as well as to the use of the polypeptide or identified compounds in the manufacture of medicaments. The present inventors have succeeded in isolating a protein from PAM membranes that seems to play a crucial role in virus entry into the cell. The elucidated nucleotide sequence encoding the protein, as well as the amino acid sequence of the protein, were compared with sequences stored in sequence databases.Type: GrantFiled: July 18, 2002Date of Patent: July 21, 2009Assignees: Intervet International B.V., Universiteit GentInventors: Maurice Pensaert, Hans Nauwynck, Nathalie Vanderheijden
-
Patent number: 7479284Abstract: The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines.Type: GrantFiled: October 11, 2005Date of Patent: January 20, 2009Assignee: Intervet International B.V.Inventors: Theodorus Petrus Maria Schetters, Bernard Pierre Dominique Carcy, Pascal Robert Drakulovski, Andre Francois Gorenflot
-
Patent number: 7465459Abstract: The invention relates to a Piroplasmid protein or an immunogenic fragment of the protein, and to a nucleic acid encoding the Piroplasmid protein or the immunogenic fragment. Furthermore, the invention relates to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising the nucleic acid. Also the invention relates to host cells comprising the cDNA fragments, recombinant DNA molecules and live recombinant carriers. Finally, the invention relates to vaccines comprising a Piroplasmid protein or an immunogenic fragment of the protein, to methods for the preparation of such vaccines, to the use of such proteins or fragments for vaccine purposes, and to diagnostic tests.Type: GrantFiled: September 14, 2004Date of Patent: December 16, 2008Assignee: Universiteit Utrecht Holding B.V.Inventors: Erik de Vries, Fasila Razzia Gaffar, Ana Patricia Yatsuda, Theodorus Cornelis Schaap
-
Patent number: 7462479Abstract: Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.Type: GrantFiled: October 2, 2007Date of Patent: December 9, 2008Assignee: Intervet International B.V.Inventors: Lillian Melson, Faris F. Jirjis
-
Patent number: 7341725Abstract: The present invention relates to the structural proteins of the causative agent of Pancreatic Disease in fish, nucleotide sequences encoding said proteins, vaccines comprising said proteins or nucleotide sequences and diagnostic kits comprising said proteins or nucleotide sequences.Type: GrantFiled: February 26, 2004Date of Patent: March 11, 2008Assignee: Intervet International B.V.Inventors: Jonathan Weston, Daniel Todd
-
Patent number: 7291342Abstract: Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.Type: GrantFiled: May 17, 2004Date of Patent: November 6, 2007Assignee: Intervet International B.V.Inventors: Lillian Melson, Faris Jirjis
-
Patent number: 7279167Abstract: This invention relates to Infectious Salmon Anaemia Virus (ISAV) antigenic polypeptides and nucleic acid molecules encoding them, as well as vaccines, transformed cells and transgenic fish. The antigenic polypeptides are able to elicit an immune response in immunized animals.Type: GrantFiled: October 16, 2002Date of Patent: October 9, 2007Assignee: Intervet International B.V.Inventors: Stephane Villoing, Eirik Biering
-
Patent number: 7264812Abstract: The present invention relates to nucleic acid sequences encoding Ostertagia ostertagi proteins and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relate to Ostertagia ostertagi proteins and immunogenic parts thereof encoded by such sequences. Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, proteins or immunogenic parts thereof and antibodies against such proteins or immunogenic thereof. Also, the inventions relates to the use of said proteins in vaccines and for the manufacture of vaccines.Type: GrantFiled: September 11, 2003Date of Patent: September 4, 2007Assignee: Universiteit GentInventors: Edwin Claerebout, Peter Geldhof, Veerle De Maere, Isabel Vercauteren, Jozef Vercruijsse
-
Patent number: 7244434Abstract: The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing protein(s), but do not produce infectious progeny virus. Such replicons can be useful for vaccine purposes.Type: GrantFiled: August 12, 2003Date of Patent: July 17, 2007Assignee: Intervet International B.V.Inventors: Martin Beer, Ilona Reimann
-
Patent number: 7150873Abstract: The present invention relates to hydrophilic Eimeria polypeptides, DNA-fragments encoding those peptides, recombinant DNA molecules comprising such DNA-fragments, live recombinant carriers comprising such DNA-fragments or recombinant DNA molecules and host cells comprising such DNA-fragments, recombinant DNA molecules or live recombinant carriers. Furthermore, the invention relates to antibodies against the polypeptides and to coccidiosis vaccines based upon said polypeptides. The invention also relates to methods for the preparation of such antibodies and vaccines, and to methods for the detection of Eimeria parasites and antibodies against Eimeria parasites.Type: GrantFiled: November 26, 2003Date of Patent: December 19, 2006Assignee: Intervet International B.V.Inventors: Theodorus Cornelis Schaap, Catharina Maria Kuiper, Arnoldus Nicolaas Vermeulen
-
Patent number: 7090849Abstract: The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines.Type: GrantFiled: February 28, 2002Date of Patent: August 15, 2006Assignee: Akzo Nobel N.V.Inventors: Theodorus Petrus Maria Schetters, Bernard Pierre Dominique Carcy, Pascal Robert Drakulovski
-
Patent number: 7090981Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.Type: GrantFiled: February 3, 2004Date of Patent: August 15, 2006Assignee: Akzo Nobel N.V.Inventors: Carla Christina Schrier, Henricus Johannes Maria Jagt
-
Patent number: 7090854Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.Type: GrantFiled: February 3, 2004Date of Patent: August 15, 2006Assignee: Akzo Nobel N.V.Inventors: Carla Christina Schrier, Henricus Johannes Maria Jagt